Donald J. Mirrlees - Concepedia

Author

Donald J. Mirrlees

AstraZeneca (United Kingdom)

Also Known As

Donald J Mirrlees, Donald J. Mirrlees, Donald Mirrlees

Publications

528

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)East Cheshire NHS Trust

About

Donald J. Mirrlees is an author at AstraZeneca (United Kingdom) specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	304
2	Biochemistry	8	8	330
3	Natural Sciences	3	3	58
4	Chemical Biology	3	3	58
5	Diabetes	2	2	176

Donald J. Mirrlees

Publications

519

Citations

H-Index

Page 1

	Year	Citations
Modification of the glyoxalase system in streptozotocin-induced diabetic rats Susan A. Phillips, Donald J. Mirrlees, Paul J. Thornalley Biochemical Pharmacology BiochemistryMedicineDiabetesGlycobiologyGlyoxalase System	1993	141
Effects of Long-Term Aldose Reductase Inhibition on Development of Experimental Diabetic Neuropathy: Ultrastructural and Morphometric Studies of Sural Nerve in Streptozocin-Induced Diabetic Rats Soroku Yagihashi, Mikiko Kamijo, Yasuo Ido, Diabetes	1990	105
Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin‐induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat Paul Taylor, Alan D. Wickenden, Donald J. Mirrlees, British Journal of Pharmacology	1994	69
Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines Fergus McTaggart, George R. Brown, Robert G. Davidson, Biochemical Pharmacology BiochemistrySqualene SynthaseOrganic ChemistryNovel 3′Pharmacology	1996	41
Ponalrestat: A potent and specific inhibitor of aldose reductase Walter H.J. Ward, Christopher M. Sennitt, Helen E. Ross, Biochemical Pharmacology Aldo-keto ReductaseBiochemistryMedicineAldose ReductaseMechanism Of Action	1990	40
The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats Richard Poulsom, Donald J. Mirrlees, Dudley C.N. Earl, Experimental Eye Research Diabetic RetinopathyBiochemistryOphthalmologySorbitol PathwayMedicine	1983	35
Quinuclidine Inhibitors of 2,3-Oxidosqualene Cyclase-Lanosterol Synthase: Optimization from Lipid Profiles George R. Brown, David M. Hollinshead, Elaine S. E. Stokes, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryPharmacotherapyChemical BiologyPharmaceutical Chemistry	1999	21
A Novel Series of 4-Piperidinopyridine and 4-Piperidinopyrimidine Inhibitors of 2,3-Oxidosqualene Cyclase−Lanosterol Synthase George R. Brown, David M. Hollinshead, Elaine S. E. Stokes, Journal of Medicinal Chemistry PharmacotherapyHeterocycle ChemistryChemical BiologyPharmaceutical ChemistryMolecular Pharmacology	2000	20
(2,6-dimethylphenylsulphonyl)nitromethane: A new structural type of aldose reductase inhibitor which follows biphasic kinetics and uses an allosteric binding site Walter H.J. Ward, Peter N. Cook, Donald J. Mirrlees, Biochemical Pharmacology Medicinal ChemistryAldo-keto ReductaseAldehyde DehydrogenaseBiochemistryBiphasic Kinetics	1991	17
Kinetic characteristics of zeneca ZD5522, a potent inhibitor of human and bovine lens aldose reductase Peter N. Cook, Walter H.J. Ward, J. Mark Petrash, Biochemical Pharmacology Aldo-keto ReductaseBiochemistryPotent InhibitorMedicineMechanism Of Action	1995	15

Page 1